Susquehanna International Group
ARQT icon

Susquehanna International Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Susquehanna International Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$210K Sell
8,900
-21,000
-70% -$536K ﹤0.01% 11605
2025
Q4 		$868K Sell
29,900
-53,300
-64% -$1.36M ﹤0.01% 7501
2025
Q3 		$1.57M Sell
83,200
-58,600
-41% -$924K ﹤0.01% 6308
2025
Q2 		$1.99M Buy
141,800
+36,200
+34% +$507K ﹤0.01% 5795
2025
Q1 		$1.65M Sell
105,600
-8,300
-7% -$117K ﹤0.01% 5974
2024
Q4 		$1.59M Buy
113,900
+64,700
+132% +$709K ﹤0.01% 5820
2024
Q3 		$458K Sell
49,200
-36,500
-43% -$360K ﹤0.01% 8673
2024
Q2 		$797K Sell
85,700
-215,700
-72% -$1.95M ﹤0.01% 7125
2024
Q1 		$2.99M Buy
301,400
+265,800
+747% +$1.98M ﹤0.01% 4527
2023
Q4 		$115K Sell
35,600
-1,600
-4% -$4.35K ﹤0.01% 11213
2023
Q3 		$198K Buy
37,200
+1,300
+4% +$11.1K ﹤0.01% 10244
2023
Q2 		$342K Buy
+35,900
New +$398K ﹤0.01% 9175
2022
Q4 		– Sell
-17,700
Closed -$338K – 12344
2022
Q3 		$338K Buy
+17,700
New +$401K ﹤0.01% 9479
2021
Q4 		– Sell
-8,800
Closed -$210K – 13070
2021
Q3 		$210K Sell
8,800
-7,000
-44% -$160K ﹤0.01% 11381
2021
Q2 		$431K Buy
15,800
+4,700
+42% +$132K ﹤0.01% 9938
2021
Q1 		$321K Buy
+11,100
New +$347K ﹤0.01% 10458

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's ARQT Position: Q1 2026 in Review

Susquehanna International Group increased its Arcutis Biotherapeutics (ARQT) stake by 1,165% in Q1 2026, buying an estimated $2.64M and bringing the position to 112,179 shares worth $2.64M. The position accounts for ﹤0.01% of the portfolio, ranked #5541.

Susquehanna International Group first reported a position in ARQT in Q2 2020 and has held it in 24 quarters since. The position peaked at $3.66M in Q2 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Susquehanna International Group held 112,179 shares of Arcutis Biotherapeutics worth $2.64M as of Q1 2026.
  • Susquehanna International Group bought 103,312 Arcutis Biotherapeutics shares in Q1 2026, an estimated $2.64M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5541 holding.
  • Susquehanna International Group first reported a position in Arcutis Biotherapeutics in Q2 2020 and has held it in 24 quarters since.
  • Susquehanna International Group's Arcutis Biotherapeutics position peaked at $3.66M in Q2 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.